Schizophrenia – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)

Schizophrenia is an often disabling psychiatric disease that usually requires long-term treatment. The primary goals of medical treatment for schizophrenia are to reduce the frequency and severity of psychotic episodes, maintain the reduction in these symptoms over the long term, and improve patients’ functional capacity. Antipsychotics are the cornerstone of schizophrenia treatment, and the numerous atypical and typical antipsychotic drug classes available result in a complex treatment algorithm. Given the genericization of key oral therapies and the availability of newer oral, transdermal, and long-acting depot antipsychotics in the United States, such as Intra-Cellular Therapies’ Caplyta, AbbVie’s Vraylar, Noven’s Secuado, and Indivior’s Perseris, competition in the U.S. market continues to intensify. As such, understanding the nuanced schizophrenia treatment landscape is essential for assessing the remaining drug opportunities in this space.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed schizophrenia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed schizophrenia patients?
  • How have newer agents such as Secuado, Caplyta, Perseris, and Vraylar been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of schizophrenia patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of schizophrenia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Alkermes, Eli Lilly, Janssen, Indivior, Intra-Cellular Therapeutics, Lundbeck, Otsuka, Sumitomo Dainippon Pharma / Sunovion Pharmaceuticals

Key drugs: Abilify Maintena, Aristada, Invega Sustenna, Invega Trinza, Latuda, Rexulti, Risperdal Consta, Vraylar, Perseris, Caplyta, Secuado

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Table of contents

  • Schizophrenia - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms CDA Schizophrenia US June 2021
    • Treatment Algorithms CDA Schizophrenia US 2021 Dashboard

launch Related Market Assessment Reports